Is 49B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6
Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 49B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 49B (€13.8) is trading below our estimate of fair value (€40.11)
Significantly Below Fair Value: 49B is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 49B?
Key metric: As 49B is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for 49B. This is calculated by dividing 49B's market cap by their current
revenue.
What is 49B's PS Ratio?
PS Ratio
6.2x
Sales
CN¥23.51b
Market Cap
CN¥146.53b
49B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Sales vs Industry: 49B is good value based on its Price-To-Sales Ratio (6.2x) compared to the European Biotechs industry average (8.1x).
Price to Sales Ratio vs Fair Ratio
What is 49B's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
49B PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
6.2x
Fair PS Ratio
8.8x
Price-To-Sales vs Fair Ratio: 49B is good value based on its Price-To-Sales Ratio (6.2x) compared to the estimated Fair Price-To-Sales Ratio (8.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.